ABIONYX Pharma Announces the Appointment of Laurent Guerci as Chief Digital & Innovation Officer
12 Luglio 2023 - 7:37PM
Business Wire
- Management of new projects
- Structuring information systems to boost pharma
development
- Focus on digitalisation and AI to support the deployment of
the innovative biotherapy strategy based on Apoa-I
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible)
(Paris:ABNX), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world's only natural recombinant ApoA-I, today announces the
appointment of Laurent Guerci as Chief Digital & Innovation
Officer.
Agricultural engineer and graduate of the CPA (Executive MBA),
Laurent Guerci has spent his entire career in information systems,
first as the founding director of a company specialized in ERP for
agricultural applications, which he sold, then as consulting
director in information systems at PWC, and finally as director of
various profit centers within the ACTIA industrial Group, where he
was in charge of developing new digital activities in France and
abroad.
He will be responsible for carrying out various projects to
structure ABIONYX Pharma, in particular the digitalisation of the
Group. ABIONYX Pharma's ambition, in support of its innovative
biotherapies strategy, is to digitalise its internal processes, its
exchanges with its pharmaceutical partners and to use its data
capital through the use of Artificial Intelligence technologies to
improve its know-how in pre-clinical and clinical studies and the
development of innovative therapies, whether in sepsis, renal
diseases or ophthalmology.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230712247349/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 94 94
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 94
Grafico Azioni Abionyx Pharma (EU:ABNX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Abionyx Pharma (EU:ABNX)
Storico
Da Mag 2023 a Mag 2024
